Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An analysis of the short-term operating activity ratios reveals a significant expansion in the time required to convert resources into cash, primarily driven by a decline in inventory efficiency. While receivables management remains stable, the overall operating cycle has lengthened considerably over the observed period.
- Inventory Management Efficiency
- A consistent downward trend is observed in inventory turnover, which decreased from 2.82 in March 2022 to 1.78 by September 2026. This decline is mirrored by the average inventory processing period, which increased from 130 days to 204 days. These metrics indicate a substantial slowdown in the movement of goods, suggesting either an increase in safety stock levels or a reduction in the velocity of sales relative to inventory holdings.
- Receivables and Payables Performance
- Receivables turnover has remained relatively stable, generally fluctuating between 6.30 and 7.63. Consequently, the average receivable collection period has shown minimal variance, consistently ranging between 48 and 58 days. Payables turnover exhibits more volatility, with values oscillating between 10.39 and 14.36, while the average payables payment period remains narrow, typically between 25 and 35 days. This suggests a consistent approach to credit collection and supplier payment terms.
- Operating and Cash Conversion Cycles
- The operating cycle has experienced a steady increase, rising from 186 days in March 2022 to 258 days by September 2026. Because the receivable collection period remained flat, this expansion is almost entirely attributable to the lengthened inventory processing period. Similarly, the cash conversion cycle has trended upward from 161 days to 231 days, indicating that more capital is tied up in operations for longer durations before being recovered as cash.
- Working Capital Utilization
- Working capital turnover exhibited initial volatility but showed a notable upward trend in the latter half of the period, reaching a peak of 1.96 by September 2026. This suggests that despite the slowing inventory turnover, the company has increased its efficiency in generating revenue relative to its net working capital investment.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Inventory Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Cost of revenue | 964,400) | 931,900) | 940,300) | 961,900) | 842,700) | 822,100) | 795,700) | 771,300) | 664,200) | 637,200) | 645,200) | 650,900) | 576,500) | 584,000) | 583,200) | 544,100) | 505,300) | 498,800) | 478,000) | ||||||
| Inventory | 2,128,200) | 2,028,700) | 1,945,100) | 1,840,000) | 1,781,900) | 1,667,000) | 1,553,600) | 1,487,200) | 1,481,700) | 1,383,900) | 1,299,300) | 1,220,600) | 1,147,500) | 1,005,200) | 946,600) | 893,200) | 837,100) | 724,000) | 653,000) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Inventory turnover1 | 1.78 | 1.81 | 1.83 | 1.86 | 1.81 | 1.83 | 1.85 | 1.83 | 1.75 | 1.81 | 1.89 | 1.96 | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 2.76 | 2.82 | 2.98 | 2.88 | 2.73 | 2.82 | 3.02 | 2.69 | 2.67 | 2.65 | 2.74 | 2.71 | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | ||||||
| Medtronic PLC | 1.98 | 1.95 | 2.02 | 2.12 | 2.06 | 2.11 | 2.10 | 2.15 | 1.95 | 1.92 | 1.91 | 2.03 | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Inventory turnover
= (Cost of revenueQ3 2026
+ Cost of revenueQ2 2026
+ Cost of revenueQ1 2026
+ Cost of revenueQ4 2025)
÷ Inventory
= (964,400 + 931,900 + 940,300 + 961,900)
÷ 2,128,200 = 1.78
2 Click competitor name to see calculations.
The analysis of operating activity reveals a consistent decline in inventory management efficiency over the observed period, characterized by a sustained decrease in the inventory turnover ratio alongside significant growth in total inventory holdings.
- Inventory Turnover Trend
- A clear downward trajectory is observed in the inventory turnover ratio, which decreased from 2.82 in March 2022 to 1.78 by September 2026. The most pronounced decline occurred between March 2022 and September 2024, during which the ratio fell from 2.82 to a low of 1.75. From December 2024 through September 2026, the ratio entered a period of relative stabilization, fluctuating narrowly between 1.78 and 1.86.
- Inventory Accumulation
- Inventory levels experienced aggressive growth, rising from 653 million USD in March 2022 to 2.13 billion USD by September 2026. This represents an increase of approximately 226% over the analyzed timeframe. The rate of inventory accumulation consistently exceeded the growth rate of the cost of revenue, which is the primary driver behind the compression of the turnover ratio.
- Cost of Revenue Growth
- The cost of revenue exhibited steady growth, increasing from 478 million USD in March 2022 to 964.4 million USD in September 2026. Although the cost of revenue more than doubled, the growth was not proportional to the expansion of inventory, indicating that the company scaled its stock levels more rapidly than its current output or sales volume.
- Operational Efficiency Insights
- The widening gap between inventory growth and cost of revenue suggests a lengthening of the operating cycle. The reduction in the turnover ratio indicates that inventory is remaining on hand longer before being recognized as a cost of sale. However, the stabilization of the ratio starting in late 2024 suggests that the company may have reached a new operational baseline or implemented a strategic inventory buffering strategy to support expanded capacity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Receivables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenue | 3,048,700) | 2,892,300) | 2,770,800) | 2,866,200) | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | ||||||
| Accounts receivable, net | 1,721,300) | 1,673,200) | 1,595,600) | 1,527,300) | 1,259,700) | 1,269,200) | 1,221,500) | 1,225,400) | 1,153,000) | 1,109,100) | 1,127,900) | 1,130,200) | 962,700) | 904,200) | 925,300) | 942,100) | 849,600) | 838,500) | 906,100) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | 6.73 | 6.59 | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 5.42 | 5.50 | 5.59 | 5.39 | 5.41 | 5.78 | 6.06 | 5.85 | 5.94 | 6.11 | 6.11 | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | ||||||
| Elevance Health Inc. | 15.41 | 14.99 | 14.30 | 16.34 | 16.80 | 14.83 | 14.42 | 18.00 | 19.84 | 17.60 | 15.98 | 18.08 | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | ||||||
| Medtronic PLC | 5.58 | 5.44 | 5.46 | 5.15 | 5.43 | 5.27 | 5.42 | 5.28 | 5.42 | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | ||||||
| UnitedHealth Group Inc. | — | 20.67 | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Receivables turnover
= (RevenueQ3 2026
+ RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025)
÷ Accounts receivable, net
= (3,048,700 + 2,892,300 + 2,770,800 + 2,866,200)
÷ 1,721,300 = 6.73
2 Click competitor name to see calculations.
The financial data exhibits a consistent upward trajectory in both top-line revenue and net accounts receivable over the period from March 31, 2022, to September 30, 2026. Revenue grew from 1,487,700 thousand US dollars to 3,048,700 thousand US dollars, while net accounts receivable increased from 906,100 thousand US dollars to 1,721,300 thousand US dollars. This proportional growth indicates that the scale of credit extended to customers has expanded in alignment with the company's increasing sales volume.
- Revenue and Receivables Correlation
- A strong positive correlation is observed between revenue growth and the balance of accounts receivable. Significant revenue peaks, such as the increase to 2,413,500 thousand US dollars in December 2024 and 2,866,200 thousand US dollars in December 2025, were accompanied by corresponding increases in net receivables. This suggests that the growth in sales is driven, at least in part, by credit-based transactions.
- Receivables Turnover Volatility
- The receivables turnover ratio demonstrates a pattern of periodic fluctuation within a relatively tight band, ranging from a minimum of 6.30 in December 2023 to a maximum of 7.63 in September 2025. This stability indicates that the company has maintained a consistent efficiency in collecting its outstanding receivables despite the substantial increase in overall business volume.
- Collection Efficiency Trends
- An analysis of the turnover ratio reveals a period of heightened collection efficiency throughout 2025, peaking in the third quarter. However, a moderate decline is noted starting in December 2025, with the ratio retreating to 6.59. For the first three quarters of 2026, the ratio stabilized between 6.59 and 6.73, suggesting a normalization of the credit-to-cash cycle following the volatility observed in late 2023 and 2025.
Overall, the operational activity regarding receivables remains stable. The company has successfully scaled its collection processes to match a near-doubling of quarterly revenue, avoiding any significant deterioration in the speed of payment collection over the analyzed timeframe.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Payables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Cost of revenue | 964,400) | 931,900) | 940,300) | 961,900) | 842,700) | 822,100) | 795,700) | 771,300) | 664,200) | 637,200) | 645,200) | 650,900) | 576,500) | 584,000) | 583,200) | 544,100) | 505,300) | 498,800) | 478,000) | ||||||
| Accounts payable | 279,500) | 277,200) | 332,900) | 255,100) | 291,200) | 266,800) | 276,200) | 193,400) | 218,700) | 194,400) | 194,400) | 188,700) | 196,200) | 199,700) | 164,100) | 147,000) | 164,200) | 149,700) | 128,100) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Payables turnover1 | 13.59 | 13.26 | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 4.22 | 4.22 | 4.56 | 4.69 | 4.40 | 4.44 | 4.46 | 4.54 | 4.42 | 4.33 | 4.19 | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | ||||||
| Elevance Health Inc. | 8.05 | 8.06 | 8.06 | 8.68 | 8.38 | 8.07 | 7.87 | 8.10 | 8.17 | 8.09 | 7.54 | 7.72 | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | ||||||
| Medtronic PLC | 4.85 | 4.64 | 4.65 | 4.75 | 5.04 | 4.85 | 4.95 | 4.65 | 5.60 | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | ||||||
| UnitedHealth Group Inc. | — | 7.98 | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Payables turnover
= (Cost of revenueQ3 2026
+ Cost of revenueQ2 2026
+ Cost of revenueQ1 2026
+ Cost of revenueQ4 2025)
÷ Accounts payable
= (964,400 + 931,900 + 940,300 + 961,900)
÷ 279,500 = 13.59
2 Click competitor name to see calculations.
Analysis of short-term operating activity reveals a consistent expansion in the scale of operations, characterized by a steady increase in the cost of revenue, coupled with periodic fluctuations in the efficiency of payables management. While the volume of procurement has grown substantially, the pace at which obligations to suppliers are settled has experienced cyclical variance.
- Cost of Revenue Growth
- A sustained upward trajectory is observed in the cost of revenue, which rose from 478,000 thousand US$ in March 2022 to 964,400 thousand US$ by September 2026. This represents an approximate doubling of expenditures over the analyzed period, indicating significant growth in production or service delivery requirements.
- Accounts Payable Dynamics
- Accounts payable exhibited a general upward trend, increasing from 128,100 thousand US$ in March 2022 to 279,500 thousand US$ in September 2026. Notable volatility is present, with a significant peak occurring in March 2026 at 332,900 thousand US$, followed by a contraction in subsequent quarters, suggesting shifts in vendor credit terms or strategic timing of payments.
- Payables Turnover Ratio Analysis
- The payables turnover ratio fluctuated between a high of 14.36 in March 2022 and a low of 10.39 in March 2025. This volatility indicates a shifting balance between the cost of revenue and the average amount owed to suppliers. The decline toward the March 2025 low coincides with a sharp increase in accounts payable, suggesting a period of extended payment windows or an increase in credit utilization.
- Recent Operational Trends
- Following the low point in early 2025, the payables turnover ratio demonstrated a recovery trend, stabilizing between 13.26 and 13.59 during the second and third quarters of 2026. This stabilization suggests a return to a more consistent payment cadence despite the overall increase in the magnitude of quarterly costs.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Working Capital Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current assets | 8,428,300) | 9,542,700) | 8,809,500) | 9,779,500) | 8,525,300) | 8,745,900) | 7,657,800) | 7,111,000) | 7,215,600) | 7,654,300) | 7,632,700) | 7,888,000) | 8,902,900) | 8,031,800) | 6,877,000) | 6,253,000) | 6,293,100) | 6,292,500) | 5,803,200) | ||||||
| Less: Current liabilities | 2,533,000) | 1,922,900) | 1,911,000) | 2,006,200) | 1,803,200) | 1,692,600) | 1,538,100) | 1,745,300) | 1,676,800) | 1,487,500) | 1,375,100) | 1,658,700) | 1,676,400) | 1,538,400) | 1,307,400) | 1,422,100) | 1,233,400) | 1,175,000) | 1,112,200) | ||||||
| Working capital | 5,895,300) | 7,619,800) | 6,898,500) | 7,773,300) | 6,722,100) | 7,053,300) | 6,119,700) | 5,365,700) | 5,538,800) | 6,166,800) | 6,257,600) | 6,229,300) | 7,226,500) | 6,493,400) | 5,569,600) | 4,830,900) | 5,059,700) | 5,117,500) | 4,691,000) | ||||||
| Revenue | 3,048,700) | 2,892,300) | 2,770,800) | 2,866,200) | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | 1.96 | 1.45 | 1.53 | 1.29 | 1.43 | 1.30 | 1.42 | 1.56 | 1.42 | 1.23 | 1.17 | 1.14 | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 6.95 | 6.33 | 4.67 | 4.27 | 3.91 | 4.17 | 4.42 | 4.63 | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | ||||||
| Elevance Health Inc. | 7.53 | 7.19 | 7.59 | 7.50 | 7.00 | 7.96 | 8.11 | 7.85 | 6.87 | 6.92 | 8.59 | 7.83 | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | ||||||
| Medtronic PLC | 2.43 | 2.47 | 2.92 | 3.07 | 3.11 | 3.22 | 2.79 | 2.90 | 2.54 | 2.57 | 2.46 | 2.47 | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | ||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Working capital turnover
= (RevenueQ3 2026
+ RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025)
÷ Working capital
= (3,048,700 + 2,892,300 + 2,770,800 + 2,866,200)
÷ 5,895,300 = 1.96
2 Click competitor name to see calculations.
The analysis of operational efficiency regarding working capital utilization demonstrates a general trend of improving productivity and revenue generation capabilities over the observed period.
- Revenue Growth Trends
- A consistent and strong upward trajectory in quarterly revenue is observed, increasing from 1.48 billion in March 2022 to 3.04 billion by September 2026. This steady expansion indicates a sustained increase in top-line performance throughout the analyzed timeframe.
- Working Capital Dynamics
- Working capital exhibited more volatility than revenue. The balance grew from 4.69 billion in March 2022, reaching a peak of 7.77 billion in December 2025. However, a notable contraction occurred in the final quarters, with the balance decreasing to 5.89 billion by September 2026. This suggests a strategic shift or a cyclical reduction in current assets relative to current liabilities toward the end of the period.
- Working Capital Turnover Efficiency
- The working capital turnover ratio reflects an overall improvement in operational efficiency. While the ratio experienced a decline in 2023, reaching a minimum of 0.95 in September of that year, it recovered strongly thereafter. A significant acceleration in efficiency is noted from December 2023 onward, culminating in a period high of 1.96 in September 2026. This trend indicates that the company has become substantially more effective at utilizing its short-term operating capital to drive sales, effectively decoupling revenue growth from the need for proportional increases in working capital.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Inventory Processing Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Inventory turnover | 1.78 | 1.81 | 1.83 | 1.86 | 1.81 | 1.83 | 1.85 | 1.83 | 1.75 | 1.81 | 1.89 | 1.96 | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average inventory processing period1 | 204 | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 132 | 129 | 123 | 127 | 134 | 130 | 121 | 136 | 136 | 138 | 133 | 135 | 139 | 132 | 118 | 108 | 113 | 109 | ||||||
| Medtronic PLC | 185 | 187 | 181 | 172 | 178 | 173 | 174 | 170 | 187 | 190 | 191 | 180 | 190 | 183 | 174 | 166 | 161 | 153 | 148 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.78 = 204
2 Click competitor name to see calculations.
An analysis of the operating activity ratios reveals a consistent decline in inventory efficiency over the observed period from March 31, 2022, to September 30, 2026. This trend is characterized by a reduction in the velocity of inventory turnover and a corresponding increase in the time required to process inventory.
- Inventory Turnover Trend
- A persistent downward trajectory is observed in the inventory turnover ratio, which decreased from 2.82 in March 2022 to 1.78 by September 2026. The most significant decline occurred between March 2022 and September 2024, where the ratio dropped to a low of 1.75. From December 2024 through September 2026, the ratio entered a period of relative stabilization, fluctuating narrowly between 1.78 and 1.86.
- Average Inventory Processing Period
- The average inventory processing period exhibits an inverse correlation to turnover, showing a substantial increase over the analyzed timeframe. The duration rose from 130 days in March 2022 to 204 days in September 2026. A period of rapid expansion is evident between September 2022 (155 days) and September 2024 (208 days). Following this peak, the processing period remained elevated, consistently staying near or above the 200-day mark for the remainder of the period.
- Operational Implications
- The data indicates a systemic slowdown in inventory movement. The transition from a 130-day cycle to a 204-day cycle suggests a significant increase in the amount of capital tied up in inventory. This trend reflects a decrease in inventory liquidity and a longer window between the acquisition of components or finished goods and their eventual sale.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Receivable Collection Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | 6.73 | 6.59 | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | 54 | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 67 | 66 | 65 | 68 | 67 | 63 | 60 | 62 | 61 | 60 | 60 | 59 | 56 | 53 | 52 | 52 | 58 | 59 | ||||||
| Elevance Health Inc. | 24 | 24 | 26 | 22 | 22 | 25 | 25 | 20 | 18 | 21 | 23 | 20 | 20 | 19 | 22 | 19 | 19 | 19 | 22 | ||||||
| Medtronic PLC | 65 | 67 | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | ||||||
| UnitedHealth Group Inc. | — | 18 | 22 | 19 | 19 | 21 | 24 | 21 | 19 | 22 | 26 | 21 | 21 | 19 | 25 | 20 | 20 | 22 | 23 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.73 = 54
2 Click competitor name to see calculations.
An analysis of short-term operating activity reveals a consistent pattern in the management of accounts receivable from March 2022 through September 2026. The efficiency of credit collection remains relatively stable, with the average receivable collection period generally fluctuating within a narrow band of 48 to 58 days.
- Average Receivable Collection Period Trends
- The collection cycle exhibits minor periodic volatility. A peak in the collection period occurred in December 2023, reaching 58 days, while the most efficient collection window was observed in September 2025, dropping to 48 days. Following this trough, the period normalized and stabilized between 54 and 55 days throughout the first three quarters of 2026.
- Receivables Turnover Correlation
- A clear inverse relationship exists between the receivables turnover ratio and the average collection period. The highest operational efficiency was recorded in September 2025, when the turnover ratio peaked at 7.63, resulting in the shortest collection period of 48 days. Conversely, the lowest turnover ratio of 6.30 in December 2023 corresponds directly with the maximum collection period of 58 days.
- Operational Stability and Credit Management
- The narrow variance in collection days suggests a disciplined approach to credit policy and a predictable payment cadence from the customer base. The lack of any sustained upward trend in the collection period indicates that the company has successfully mitigated credit risk and maintained consistent liquidity from its operating receivables over the analyzed timeframe.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Cycle
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 204 | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | ||||||
| Average receivable collection period | 54 | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Operating cycle1 | 258 | 256 | 254 | 251 | 249 | 250 | 249 | 254 | 261 | 254 | 249 | 244 | 234 | 216 | 215 | 216 | 206 | 190 | 186 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 199 | 195 | 188 | 195 | 201 | 193 | 181 | 198 | 197 | 198 | 193 | 194 | 195 | 185 | 170 | 160 | 171 | 168 | ||||||
| Medtronic PLC | 250 | 254 | 248 | 243 | 245 | 242 | 241 | 239 | 254 | 258 | 258 | 250 | 260 | 250 | 236 | 230 | 224 | 216 | 211 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 204 + 54 = 258
2 Click competitor name to see calculations.
The operating cycle exhibits a significant long-term expansion, reflecting an increase in the time required to convert operational investments back into cash. This trend is primarily driven by a substantial prolongation of the inventory processing phase, while the efficiency of receivable collections has remained relatively constant throughout the analyzed period.
- Average Inventory Processing Period
- A pronounced upward trend occurred between March 31, 2022, and September 30, 2024, during which the processing period increased from 130 days to a peak of 208 days. Following this peak, the metric entered a period of relative stabilization, oscillating between 196 and 204 days through September 30, 2026. This indicates a significant slowdown in inventory turnover or a strategic increase in stock levels that persisted over the long term.
- Average Receivable Collection Period
- The collection period remained stable, characterized by minimal volatility. The duration fluctuated within a narrow band of 48 to 58 days across the entire timeframe. This consistency suggests that credit management policies and customer payment behaviors have remained predictable and efficient, contributing negligible variance to the overall operating cycle.
- Operating Cycle
- The total operating cycle grew from 186 days in March 2022 to a maximum of 261 days in September 2024, eventually settling at 258 days by September 30, 2026. The strong positive correlation between the operating cycle and the inventory processing period confirms that inventory management is the primary driver of working capital duration. The result is a longer timeframe during which capital is tied up in the production and sales process.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Payables Payment Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Payables turnover | 13.59 | 13.26 | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average payables payment period1 | 27 | 28 | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 87 | 87 | 80 | 78 | 83 | 82 | 82 | 80 | 83 | 84 | 87 | 80 | 85 | 82 | 88 | 78 | 86 | 91 | ||||||
| Elevance Health Inc. | 45 | 45 | 45 | 42 | 44 | 45 | 46 | 45 | 45 | 45 | 48 | 47 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | ||||||
| Medtronic PLC | 75 | 79 | 79 | 77 | 72 | 75 | 74 | 78 | 65 | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | ||||||
| UnitedHealth Group Inc. | — | 46 | 46 | 46 | 49 | 49 | 50 | 47 | 48 | 47 | 50 | 49 | 51 | 52 | 53 | 50 | 52 | 53 | 54 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 13.59 = 27
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a fluctuating but generally contained cycle regarding the settlement of obligations to suppliers. The company maintains a relatively tight window for payables, with the payment period typically oscillating between 25 and 35 days throughout the observed timeframe.
- Average Payables Payment Period
- The duration required to settle accounts payable exhibits periodic expansion and contraction. A minimum payment period of 25 days was recorded in March 2022, while a peak of 35 days occurred in March 2025. The payment cycle shows a tendency to lengthen during certain quarters—notably reaching 33 days in June 2023 and maintaining levels between 32 and 35 days during the first half of 2025—before contracting again. By September 2026, the period had returned to 27 days, suggesting a consistent return to a shorter settlement cycle.
- Payables Turnover Ratio
- The payables turnover ratio demonstrates an inverse correlation with the payment period, moving within a range of 10.39 to 14.36. The highest turnover rate of 14.36 in March 2022 corresponds with the shortest payment period. Conversely, the lowest turnover ratio of 10.39 in March 2025 aligns with the maximum payment period of 35 days. This indicates that while there are fluctuations in the velocity of payments, the company avoids extreme deviations in its credit management.
- Operational Trends and Volatility
- A pattern of moderate volatility is observed, characterized by short-term peaks in the payment period followed by corrections. For instance, the increase to 33 days in mid-2023 was followed by a decrease to 26 days by December 2024. Similar volatility is evident in 2025 and 2026, where the payment period shifted from 35 days in March 2025 down to 27 days in December 2025, then rose to 34 days in March 2026 before declining again. These movements suggest tactical adjustments in cash flow management or variations in supplier terms over time.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cash Conversion Cycle
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 204 | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | ||||||
| Average receivable collection period | 54 | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Average payables payment period | 27 | 28 | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Cash conversion cycle1 | 231 | 228 | 220 | 224 | 216 | 218 | 214 | 228 | 230 | 226 | 220 | 215 | 203 | 183 | 187 | 190 | 176 | 161 | 161 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 112 | 108 | 108 | 117 | 118 | 111 | 99 | 118 | 114 | 114 | 106 | 114 | 110 | 103 | 82 | 82 | 85 | 77 | ||||||
| Medtronic PLC | 175 | 175 | 169 | 166 | 173 | 167 | 167 | 161 | 189 | 186 | 183 | 159 | 182 | 171 | 157 | 148 | 153 | 149 | 147 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 204 + 54 – 27 = 231
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a pronounced upward trajectory over the analyzed period, indicating a significant increase in the time required to convert resource inputs into cash flows. Starting at 161 days in March 2022, the cycle climbed steadily to reach 231 days by September 2026, representing a substantial expansion of the working capital cycle.
- Average Inventory Processing Period
- A consistent and significant upward trend is observed in the inventory processing period. The duration increased from 130 days in March 2022 to a peak of 208 days in September 2024, eventually stabilizing around 204 days by September 2026. This represents the primary driver of the overall increase in the cash conversion cycle, suggesting a slowdown in inventory turnover or a strategic increase in safety stock levels.
- Average Receivable Collection Period
- The collection period remained relatively stable throughout the period, fluctuating within a narrow range between 48 and 58 days. There is no discernible long-term upward or downward trend, indicating that credit policies and collection efficiencies have remained consistent despite the changes in inventory management.
- Average Payables Payment Period
- The payment period shows moderate volatility but remains within a constrained range of 25 to 35 days. While there were brief increases, such as the peak of 35 days in March 2025, the period returned to 27 days by September 2026. The lack of a significant increase in the payables period means that the company has not utilized extended vendor payment terms to offset the lengthening inventory cycle.
The analysis indicates that the extension of the cash conversion cycle is almost exclusively attributable to the increase in the average inventory processing period. Because the receivable collection and payables payment periods remained essentially flat, the overall liquidity cycle has lengthened in direct proportion to the time inventory remains on hand. This pattern suggests a growing imbalance between the speed of inventory movement and the timing of cash inflows and outflows.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?